Panuveitis Treatment Market Report 2026

The panuveitis treatment market size has grown strongly in recent years. It will grow from $4.35 billion in 2025 to $4.74 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited access to ophthalmology specialists, dependence on corticosteroid therapies, lack of advanced diagnostic tools, low awareness of panuveitis complications, fragmented treatment infrastructure.

The panuveitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in biologic and immunotherapy drugs, increasing prevalence of autoimmune and infectious eye disorders, growth of teleophthalmology and digital monitoring, rising investments in ai-based diagnostics, expansion of hospital and specialty clinic distribution channels. Major trends in the forecast period include rising adoption of biologic and targeted therapies, integration of teleophthalmology and remote monitoring, ai-assisted diagnostic tools for uveitis, growth of personalized eye care solutions, expansion of specialized ophthalmology centers.

The rising prevalence of autoimmune disorders is expected to drive the growth of the panuveitis treatment market going forward. Autoimmune disorders are increasing due to a combination of genetic susceptibility, environmental influences such as pollution and dietary changes, and greater exposure to infections and stressors that can trigger immune system dysregulation. These conditions contribute to progress in panuveitis treatment by encouraging research into immune system modulation, as many cases of panuveitis are associated with autoimmune activity. For example, in May 2023, the University of Oxford, a UK-based research university, reported that autoimmune disorders affect 10% of the global population, with 13% of women and 7% of men impacted. Therefore, the growing prevalence of autoimmune disorders is fueling the expansion of the panuveitis treatment market.

Companies operating in the panuveitis treatment market are increasingly focusing on the development of innovative therapies, such as oral dual TYK2/JAK1 inhibitors, to strengthen their competitive positioning. These small-molecule immunomodulators suppress multiple pro-inflammatory cytokine pathways, helping to reduce intraocular inflammation while offering the convenience of oral administration. For instance, in April 2024, Priovant Therapeutics, a US-based biotechnology company, reported that its oral agent brepocitinib, which inhibits TYK2 and JAK1, demonstrated strong efficacy in a mid-stage clinical study for non-infectious uveitis by reducing macular edema in several patients. Key benefits of this approach include broad cytokine inhibition, once-daily oral dosing, and decreased dependence on intravitreal injections. However, potential risks include systemic immunosuppression and off-target effects, highlighting the need for careful long-term monitoring.

In July 2023, Harrow Health Inc., a US-based company, acquired Santen for an undisclosed amount. Through this acquisition, Harrow aims to broaden its portfolio by integrating Santen’s expertise in delivering innovative therapies for uveitis and panuveitis. Santen Pharmaceutical Co. Ltd. is a Japan-based company specializing in treatments for panuveitis.

Major companies operating in the panuveitis treatment market are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Allergan Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyeGate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Graybug Vision Inc., Aciont Inc., Clearside Biomedical Inc., Aldeyra Therapeutics Inc., UCB S.A., Amgen Inc., Sanofi S.A., Galapagos NV, Kiora Pharmaceuticals Inc., ONL Therapeutics, Eyevensys, Nicox S.A., Abbott Laboratories.

North America was the largest region in the panuveitis treatment market in 2025. The regions covered in the panuveitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the panuveitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the panuveitis treatment market by increasing costs for imported biologics, immunotherapy agents, and advanced ophthalmic diagnostic tools. Hospital pharmacies, specialty clinics, and home care providers in north america, europe, and asia-pacific are most affected due to import reliance. While tariffs create cost pressures, they also encourage local manufacturing, stimulate innovation in targeted therapies, and strengthen regional supply chain resilience.

The panuveitis treatment market research report is one of a series of new reports that provides panuveitis treatment market statistics, including panuveitis treatment industry global market size, regional shares, competitors with a panuveitis treatment market share, detailed panuveitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the panuveitis treatment industry. This panuveitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Panuveitis is a serious inflammatory condition affecting all layers of the eye’s uvea, including the iris, ciliary body, and choroid, and it may also involve the retina, vitreous humor, optic nerve, or eye lens. Treating panuveitis is crucial to control inflammation, ease symptoms, and prevent vision loss or disease-related complications.

The main drug classes used in panuveitis treatment include anti-inflammatory agents, antimicrobial drugs, immunotherapy, and targeted therapies. Anti-inflammatory agents are substances or treatments intended to reduce inflammation in the body. These therapies are administered through oral and topical routes and are used across various settings, including hospitals, home care, specialty clinics, and other healthcare facilities.

The panuveitis treatment market consists of revenues earned by entities by providing services such as immunosuppressive therapy, adjunctive therapies, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The panuveitis treatment market also includes sales of corticosteroids, biogenic agents, and intravitreal implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.